Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 70 results for glaucoma

  1. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  2. Treatment for people with an IOP of 22 or 23 mmHg:- What is the clinical and cost effectiveness of treating an intraocular pressure (IOP) of 22 or 23 mmHg in people with normal optic discs and visual fields?

    important- The only proven intervention for preventing and controlling glaucoma is lowering IOP. It has been widely accepted that the...

    Research recommendation
    Published
    1 February 2022

  3. Intraocular lens insertion for correction of refractive error, with preservation of the natural lens (HTG183)

    Evidence-based recommendations on intraocular lens insertion for correction of refractive error, with preservation of the natural lens. This involves inserting an artificial lens inserted into the eye through a small cut made in the cornea.

    HealthTech guidance
    Published
    25 February 2009
    View recommendations

    Sections for HTG183

  4. Arteriovenous crossing sheathotomy for branch retinal vein occlusion (HTG211)

    Evidence-based recommendations on arteriovenous crossing sheathotomy for branch retinal vein occlusion. This involves cutting the sheath around the vessels and physically separating them where they cross to improve blood flow through the vein.

    HealthTech guidance
    Published
    24 March 2010
    View recommendations

    Sections for HTG211

  5. Photorefractive (laser) surgery for the correction of refractive errors (HTG107)

    Evidence-based recommendations on photorefractive (laser) surgery for the correction of refractive errors. This involves using a special laser to permanently change the shape of the cornea.

    HealthTech guidance
    Published
    22 March 2006
    View recommendations

    Sections for HTG107

  6. Laser correction of refractive error following non-refractive ophthalmic surgery (HTG256)

    Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.

    HealthTech guidance
    Published
    23 March 2011
    View recommendations

    Sections for HTG256

  7. Omalizumab for treating severe persistent allergic asthma (TA278)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma in people aged 6 and over.

    Technology appraisal guidance
    Published
    24 April 2013
    View recommendations

    Sections for TA278

  8. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

    Technology appraisal guidance
    Discontinued

  9. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA671

  10. Boston Keratoprosthesis Type I for corneal blindness (MIB91)

    NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .

    Medtech innovation briefing
    Published
    18 January 2017

  11. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

    Technology appraisal guidance
    Published
    26 July 2017
    View recommendations

    Sections for TA460

  12. Ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma (IPG605)

    October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.

    Withdrawn guidance

  13. Long-term effectiveness of selective laser trabeculoplasty: What is the long-term effectiveness and cost effectiveness of selective laser trabeculoplasty as a first-line treatment compared with intraocular pressure-lowering eye drops in ocular hypertension or COAG in adults?

    applicable) Source guidance details Comes from guidance Glaucoma: diagnosis and management Number NG81 Date issued

    Research recommendation
    Published
    1 February 2022

  14. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    Discontinued Reference number: GID-TA11146

    Technology appraisal guidance
    Discontinued

  15. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 March 2017